
Pharma stocks, particularly Contract Development and Manufacturing Organisation (CDMO) companies, experienced a sharp reversal on Monday with shares falling up to 10% amid profit booking. According to Business Standard, the Nifty Pharma index was the top loser among sectoral indices, down 1.8% as against a 0.26% rise in the Nifty 50 at 02:47 PM on Monday. This dramatic decline represents a stark contrast to the strong performance that had seen these stocks surge up to 89% over six months as reported by Stock Market News.
Laurus Labs emerged as the worst hit with shares plunging 10% to ₹2,190 amid heavy volume, with the average trading volume nearly doubling as 6.3 million shares changed hands on NSE and BSE. Sai Life Sciences shares slipped 7.4%, while Divi's Laboratories was down 4% and Piramal Pharma shed 3%. Other major pharma stocks including Wockhardt, Abbott India, Ipca Laboratories, Biocon and Mankind Pharma from the Nifty Pharma index declined in the range of 1-2%. Dishman Carbogen Amcis and Innova Captab from the BSE Healthcare index tanked 18% and 14% respectively, while Solara Active Pharma Sciences and Viyash Scientific plunged 9% each.
Despite Monday's sharp decline, the annual performance of these pharma stocks remains impressive. According to Business Standard, Laurus Labs and Sai Life Sciences have outperformed the market by zooming 101% each in calendar year 2026, while Divi's Laboratories surged 73% and *Piramal Pharma 45%**. In comparison, the BSE Sensex was down 4% during the same period. This demonstrates that while short-term profit booking has caused temporary volatility, the long-term fundamentals of these CDMO companies continue to attract investor interest.
Analysts at Jefferies believe Indian CRDMOs with strong Pharma/Big Pharma relationships will deliver superior financial and stock price returns compared to CRDMOs whose growth is driven by Biotech customers. As reported by Business Standard, innovators increasingly prefer partners that can support molecules from early development through commercial manufacturing, reducing supply chain complexity via end-to-end solutions. The brokerage emphasizes that higher exposure to CDMO services versus Clinical Research Organization (CRO) remains important, as CDMO revenues are generally stickier and more scalable. Jefferies believes Divi's and Laurus offer among the strongest large-scale manufacturing capabilities, while execution remains the most important criteria for CRDMO clients encompassing turnaround times, product quality, audit outcomes, reliability, and regulatory compliance.